Drug intelligence / Profile preview

cytostatin

Development stage: Preclinical
Modality: Small Molecules

Overview

Cytostatin (CTS) is a novel small molecule isolated from a microbial cultured broth that functions as a selective inhibitor of protein phosphatase 2A (PP2A). It has demonstrated anti-metastatic activity, particularly against B16 melanoma pulmonary metastasis, by augmenting natural killer (NK) cells and increasing mRNA expression of Flt-3 ligand in bone marrow cells. Additionally, cytostatin inhibits cell adhesion to the extracellular matrix and can induce apoptosis.

Targets

PP2A (Protein phosphatase 2A)

Beyond the preview

Go deeper on cytostatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cytostatin.

Explore the full profile